Maze Therapeutics is eyeing a $113 million initial public offering a little under two months after revealing a $115 million ...

Akero Therapeutics claimed a win in severe MASH on Monday morning, as the company’s candidate efruxifermin showed a 24% ...

KEY TAKEAWAYS: 70% of Sponsors miss their milestones by an average of eight months, suggesting the clinical trial recruitment ...

Eisai and Biogen scored an approval for once-monthly IV maintenance dosing of their Alzheimer’s drug Leqembi, as part of what ...

A London-based biotech has emerged from stealth with a personalized T cell therapy platform that it says could create ...